References
- COVID-19 clinical research coalition. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. Lancet. 2020;395(10233):1067–1072.
- Bauchner H, Fontanerosa PB. Randomized clinical trials and COVID-19. Managing expectations. JAMA. 2020;323(22):2262–2263. .
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalised with severe COVID-19. N Engl J Med. 2020;382(19):1787–1799. .
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1) :105949.
- The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. Preliminary Report. N Engl J Med. 2020 Jul 17. Online ahead of print. DOI:https://doi.org/10.1056/NEJMoa2021436
- Deftereos SG, Giannopoulus G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflamatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019. JAMA Network Open. 2020;3(6):e2013136. .
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020 May 22:NEJMoa2007764. Online ahead of print. DOI: https://doi.org/10.1056/NEJMoa2007764
- Hinton DM Remdesivir FDA letter of EUA authorization. May 1, 2020. [Cited 2020 Jun 29]. Available fromhttps://www.fda.gov/media/137564/download.
- European Medicines Agency. First COVID-19 treatment recommended for EU authorization. 25 June 2020. EMA/264817/2020. [Cited 2020 Jun 29]. Available from. https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authorisation_en.pdf.
- Spiteri G, Fielding J, Diercke M, et al., First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9): 2000178. .
- Holshue ML, DeBolt C, Lindquist S, et al., First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10): 929–936. .
- International Committee of Medical Journal Editors (ICMJE). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. [Cited 2020 Jun 29]. Available from: http://www.icmje.org/recommendations/
- U.S. Food and Drug Administration. Section 801 of the food and drug administration amendments act of 2007. [Cited 2020 Jun 29]. Available from: https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf
- Katheron I, Sachin K, Amy B, et al. An independent appraisal and re-analysis of hydroxychloroquine treatment for COVID-19. Swiss Med Wkly. 2020;150:w20262.
- Hinton DM Chloroquine phosphate or hydroxychloroquine sulfate FDA letter of EUA authorization. March 28, 2020. [Cited 2020 Jun 29]. Available from: https://www.fda.gov/media/136534/download
- Al-Durra M, Nolan RP, Seto E, et al. Prospective registration and reporting of trial number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and declaration of Helsinki recommendations. BMJ. 2020;369:m982.
- NIAID office of communications. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. 29 April 2020. [Cited 2020 Jun 29]. Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
- Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol. 2020;123:120–126.
- RECOVERY chief investigators. No clinical benefit from use of hydroxychloroquine in hospitalized patients with COVID-19. Press release 5 June 2020. [Cited 2020 Jun 29]. Available from: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19
- Lowe D Anti IL-6 for coronavirus patients: does it work, or not? Science Translational Medicine blog. 27 April 2020. [Cited 2020 Jun 29]. Available from: https://blogs.sciencemag.org/pipeline/archives/2020/04/27/anti-il-6-for-coronavirus-patients-does-it-work-or-not
- Sánchez-Guijo F, García-Arranz M, López-Parra M, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinMed. 2020. online first. DOI:https://doi.org/10.1016/j.eclinm.2020.100454.
- Viergever RF, Karam G, Reis A, et al. The quality of registration of clinical trials: still a problem. PLoS ONE. 2014;9(1):e84727. .
- Fleminger J, Goldacre B. Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European union clinical trials register. PLoS ONE. 2018;13(3):e0193088.
- Chaturvedi N, Mehrotra B, Kumari S, et al. Some data quality issues at ClinicalTrials.gov. Trials. 2020;20(1):378. .